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Abstract
Study objectives—The objective of this
study was to evaluate the eVectiveness of a
mass vaccination programme carried out
in Catalonia (Spain) in the last quarter of
1997 in response to an upsurge of sero-
group C meningococcal disease (SCMD).
Design—Vaccination coverage in the 18
month to 19 years age group was investi-
gated by means of a specific vaccination
register. Vaccination eVectiveness was cal-
culated using the prospective cohort
method. Cases of SCMD were identified
on the basis of compulsory reporting and
microbiological notification by hospital
laboratories. Vaccination histories were
investigated in all cases. Unadjusted and
age adjusted vaccination eVectiveness re-
ferred to the time of vaccination and the
corresponding 95% confidence intervals
(CI) were estimated at 6, 12, 18 and 24
months of follow up.
Setting—All population aged 18 months to
19 years of Catalonia.
Main results—A total of seven cases of
SCMD were detected at six months of fol-
low up (one in the vaccinated cohort), 12
cases at 12 months (one in the vaccinated
cohort), 19 cases at 18 months (two in the
vaccinated cohort) and 24 at 24 months
(two in the vaccinated cohort). The age
adjusted eVectiveness was 84% (95%CI 30,
97) at six months, 92% (95%CI 63, 98) at 12
months, 92% (95% CI 71, 98) at 18 months
and 94% (95%CI 78, 98) at 24 months. In
the target population, cases have been
reduced by more than two thirds (68%)
two years after the vaccination pro-
gramme. In the total population the
reduction was 43%.
Conclusion—Vaccination eVectiveness has
been high in Catalonia, with a dramatic
reduction in disease incidence in the
vaccinated cohort accompanied by a rel-
evant reduction in the overall population.
Given that vaccination coverage was only
54.6%, it may be supposed that this vacci-
nation eVectiveness is attributable, in
part, to the herd immunity conferred by
the vaccine.
(J Epidemiol Community Health 2001;55:283–287)
Meningococcal disease is endemic in Spain,
with hyperendemic episodes taking place every
10–15 years, which lead to higher incidence
rates, such as in the 1979 upsurge that reached
a level of 17 per 100 000 inhabitants.1
In the past, serogroup B meningococcal dis-
ease was predominant, causing almost 80% of
cases, with serogroups C and A next. However,
this situation has changed. Serogroup A disap-
peared during the 1990s and from 1993
serogroup C meningococcal disease (SCMD)
has increased, overtaking the declining number
of serogroup B cases in 1996.2
A marked rise in SCMD was registered from
mid-1996 with serogroup C becoming the
main serogroup in virtually all the regions of
Spain. This was accompanied by the appear-
ance of a new serogroup C strain—
C:2b:P1.2,5—which in some communities led
to higher case fatality rates.2
Widespread media coverage of the upsurge
caused considerable social alarm, which was
heightened by the majority involvement of
infants and adolescents.
The north western Spanish region of Gali-
cia, where the upsurge first appeared, decided,
in 1996, to respond with a campaign of mass
vaccination of the 18 months to 19 years age
group,3 a strategy that was taken up by La Rioja
and Cantabria in early 1997. The other
regions, except Andalusia, Navarra and the
Canary Islands, decided to adopt this policy
and carry out mass vaccination during the last
three months of 1997.
The campaign took place in the last quarter
of 1997 in Catalonia, with free vaccination tak-
ing place in primary health and paediatric cen-
tres. In the 18 months to 19 years age group,
overall coverage was 54.6%, reaching 65.2% in
the 18 months to 4 years group, 77.8% in the
5–9 years group, 60.8% in the 10–14 years
group and only 31.4 % among 15–19 year olds.
The campaign was estimated to have cost
around 4.5 million Euros.
Preliminary results after 6 and 12 months of
follow up were presented at the 4th Europe-
ance Conference on Vaccinology.4
In this article, mass vaccination eVectiveness
after 6, 12, 18 and 24 months of follow up is
evaluated.
Methods
In Catalonia it is compulsory to report any
suspected case of meningococcal disease to the
health authorities. In all reported cases,
cerebrospinal fluid and blood are cultivated to
isolate the germ and identify the serogroup. In
all confirmed cases of serogroup C, vaccination
status is investigated.
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All confirmed cases from January 1996 to
June 1999 have been included in the descrip-
tive study.
Vaccination eVectiveness (VE) was esti-
mated using the cohort method applied to
confirmed cases reported during the period 1
January 1998 to 31 December 1999. For the
calculation the following formula was used5:
Where Inv is the incidence rate in the unvac-
cinated cohort, and Iv the incidence rate in the
vaccinated cohort. The number of individuals in
the target population was obtained from the last
census returns (1996).6 It was assumed that in
these age groups the mortality is negligible.
For unadjusted vaccination eVectiveness
95% confidence intervals (95% CI) were
calculated by the Taylor series,7 a method
based on the asymptotic normality of the log
transformation of the quotient of two propor-
tions (see appendix).
The 95% CI of VE were calculated on the
basis of the upper and lower limits of the relative
risk (RR). Estimates of relative risk (RR) and
95% CI were calculated with and without strati-
fication for the age at the time of vaccination.
To obtain lower and upper limits of VE the
following formulas were used:
Lower limit of VE = (1−RRu) × 100, where
RRu is the upper limit of RR.
Upper limit of VE = (1−RRl ) × 100, where
RRl is the 95% Cl of the lower limit of RR.
The age adjusted vaccination eVectiveness
was obtained from the Mantel-Haenzel estima-
tor and the 95% CI were calculated by the
binomial likelihood method.8
For these calculations we have assumed that
the unvaccinated population is identical to the
vaccinated population in all characteristics that
might aVect both the transmission of the causal
agent and the development of the disease.
The calculations have been made for 6, 12
and 18, and 24 months follow up periods.
Results
Table 1 shows the distribution of all confirmed
cases of meningococcal disease according to
the serogroup during the period 1996–1999.
A substantial reduction in the incidence of
SCMD occurred during the follow up period.
In total, during 1998, 28 cases of SCMD were
reported, in comparison with the 77 reported
during the preceding year. In the target
vaccination age group, cases were reduced after
24 months of follow up by more than two
thirds (16 cases in 1999 compared with 50 in
1997). The cases in this age group occurred
almost exclusively in unvaccinated subjects (22
cases) with only two cases occurring in
vaccinated children. It should be noticed that
the incidence of unvaccinated cases was higher
in older children, the age group with lower vac-
cination coverage. In the total population the
reduction was also relevant (43%).
The target population according to the 1996
census returns was 1 273 348 and the global
vaccination estimated vaccination coverage was
54.6, although this figure changed over age
groups (see table 2). Thus, the vaccinated
cohort was 694 814 subjects and the unvacci-
nated one 578 534. So, for the follow up period
of 24 months, the number of persons year for
each cohort was 1 389 628 and 1 157 068
respectively. The number of SCMD during the
24 months follow up period was 24 (two in the
vaccinated cohort and 22 in the unvaccinated
cohort). Thus, the incidence rate in the
vaccinated cohort was 0.14 per 100 000
persons per year and in the unvaccinated one
1.90 per 100 000 persons per year. The unad-
justed vaccination eVectiveness was 92%; 95%
CI, 68 to 98%.
These calculations by periods of follow up
(6, 12, 18 and 24 months) are shown in table 3.
No relevant diVerences have been observed in
vaccination eVectiveness according to the
duration of follow up. Adjusted vaccination
eVectiveness shows similar results with nar-
rower confidence limits.
Table 1 Distribution of confirmed cases of meningococcal disease in Catalonia, 1996–1999
1996 1997 1998 1999
Cases (n) % Cases (n) % Cases (n) % Cases (n) %
Serogroup B 123 63.4 102 54.6 77 70.6 113 74.8
Serogroup C total 64 33.0 77 41.2 28 25.7 33 21.9
Serogroup C <18 months 2 1.0 13 7.0 4 3.7 9 6.0
Serogroup C 18 months–19 years 49 25.3 50 26.8 13 11.9 16 10.6
Other serogroups 2 1.0 1 0.5 0 0 1 0.7
Non-groupable 5 2.6 7 3.7 4 3.7 4 2.6
Total 194 100 187 100 109 100 151 100
Table 2 Distribution of cases of serogroup C meningococcal disease according to the period of follow up and the vaccination status
Age at the time of
vaccination
Period of follow up
6 months 12 months 18 months 24 months
Vaccinated Unvaccinated Vaccinated Unvaccinated Vaccinated Unvaccinated Vaccinated Unvaccinated
18 months–4 years 1 1 1 1 2 4 2 7
5–9 years 0 0 0 0 0 2 0 2
10–14 years 0 0 0 2 0 3 0 3
15–19 years 0 5 0 8 0 8 0 10
Total 1 6 1 11 2 17 2 22
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Discussion
Age adjusted vaccination eVectiveness accord-
ing to the cohort method in the target popula-
tion 24 months after the end of the vaccination
programme is very high (94%).
It is worth pointing out that eVectiveness has
remained stable (over 90%) during the last
three periods analysed, and does not seem to
diminish over the time since vaccination,
although it must be remembered that the total
follow up period is short and the number of
cases is low.
The results of the mass meningococcal
vaccination programme of children and young
people in Catalonia measured after 24 months
of follow up are encouraging and seem to con-
firm a high level of eVectiveness of the vaccina-
tion programme in the control of SCMD, at
least in the short-term. It is noteworthy that the
reduction observed in SCMD after the inter-
vention was not observed in serogroup B (table
1). A similar decrease of SCMD was not
observed in the regions of Spain that decided
not to carry out a mass vaccination.4
Given the social awareness of meningococcal
disease we estimate that almost 100% of cases
are notified, and that in most of them the sero-
group is identified.
Although possible, we believe that the prob-
ability that information or misclassification
bias has occurred is very low. The data on cases
come from a comprehensive surveillance sys-
tem, which includes compulsory notification of
the disease by clinicians and the laboratory
notification of positive cultures to the Micro-
biological Notification System of Catalonia.
So, probably, all confirmed serogroup C
meningococcal disease cases in Catalonia were
included in the study. The information on the
antecedents of the vaccination was collected by
field epidemiologists in all cases, minimising
the likelihood of misclassification bias. We do
not think that the vaccination uptake rate was
influenced by any other important factors
because the vaccine was free to the point of
delivery for all the children and young people
living in Catalonia.
The results of the meningococcal serogroup
C vaccination programme of Catalan children
and young people carried out during the last
three months of 1997 are better than those
obtained in the six major studies of eYcacy
(results in optimal conditions) and eVective-
ness (results in real conditions of use) carried
out in diVerent countries during the past 20
years (table 4).9–14
Noteworthy is a reduction in cases among
children under 18 months (only four cases in
1998 and nine cases in 1999 against 13 in
1997), which suggests the existence of herd
immunity. This reduction has been achieved
with relatively low levels of vaccination cover-
age (54.6%). Peltola et al15 observed a similar
phenomenon in a study of the eVectiveness of
the meningococcal A vaccination carried out in
Finland in 1994, in the framework of a mass
vaccination campaign of children in those areas
with high disease incidence. A vaccination cov-
erage of 38% was suYcient to reduce cases in
unvaccinated subjects by 40%. Also in Finland,
a vaccination coverage of 40% among military
recruits was suYcient to contain an epidemic
among the military, which however, continued
unabated in the general population.16
These excellent epidemiological results have
been achieved although studies of immunity in
vaccinated children in diVerent regions of
Spain indicate that the proportion of vacci-
nated individuals who retain bactericidal titres
>1:8 decrease rapidly, especially in children
under 6 years,17–19 which is in agreement with
the results obtained recently in the USA and
Canada with current licensed vaccines.20–22
The decision to vaccinate was taken without
a prior cost-benefit analysis. However, in light
of the results obtained, a thorough economic
Table 3 Meningococcal C vaccination eVectiveness by periods of follow up. Catalonia, 1998–1999
Period of follow up
Vaccinated cohort Unvaccinated cohort
Vaccination eVectiveness
Unadjusted Adjusted
Person years Cases Person years Cases % 95% CI % 95% CI
6 months 347 407 1 289 267 6 86 −15, 98 84 30, 97
12 months 694 814 1 578 534 11 92 41, 99 92 63, 98
18 months 1 042 221 2 867 801 17 90 58, 98 92 71, 98
24 months 1 389 628 2 1 157 068 22 92 68, 98 94 78, 98
Table 4 EYcacy and eVectiveness* of meningococcal C vaccine in published studies
Country (year) Author Type of study
Study population
Design
Follow up
period
EYcacy/
eVectiveness
% 95% CINumber Age
USA (1969) Artenstein et al9 EYcacy 68 000 Military recruits Randomised controlled trial 2 months 87† 57, 100†
USA (1969/1970) Gold et al10 EYcacy 75 000 Military recruits Randomised controlled trial 2 months 88† 52, 100†
Brazil (1972) Taunay et al11 EYcacy 135 000 6–36 months Randomised controlled trial 17 months NS
(24–36 months) (67)† (8, 89)†
Italy (1987/1989) Biselli et al12 EVectiveness 300 000 Military recruits Incidence 12 months 91† 30, 99†
Quebec (1992/1993) De Walls et
al13
EVectiveness 1.7 million 6 months–20 years Incidence 4 years 79 53, 91
(6 months–4 years) (72) (5, 91)
Gregg County (1993/1995)
Rosenstein et al14
EVectiveness 17 cases 2–29 years Case-control 85 27, 97
84 controls
Catalonia (Spain) 1998–99 EVectiveness 1.27 million 18 months–19
years
Incidence 12 months 92 63, 98
18 months 92 71, 98
24 months 94 78, 98
*Data in parentheses refer to specific population subgroups. †Recalculated by Rosenstein et al.14
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analysis (cost-benefit and cost eVectiveness) is
currently underway to investigate the eYciency
of the programme.
The seroprevalence study carried out in
Cantabria 10 months after the mass vaccina-
tion campaign supports the hypothesis that in
this vaccination, there seems to exist no clear
correlation between immunogenicity (at least,
as it is currently measured) and the protective
eYcacy of the vaccine; in this study only 6.9%
of vaccinated children between 18 months to 5
years retained bactericidal titres 10 months
after vaccination. In the 6–11 years age group,
this percentage was 51.3%.17 However, no
cases of SCMD were observed in vaccinated
children in these age groups during 1998 in this
region.
So, the distinction between immunogenicity
and eVectiveness should be taken into account,
because results are not always coincident. In
this case, challenging current thinking on this
issue,20–22 results in the field are superior to
those that could have been expected from
immunogenicity studies.
The conjugation with proteins of the capsu-
lar polysaccharide converts it into T dependent
antigen and makes the vaccine immunogenic in
breast feeding babies and also generates
immunological memory, thus ensuring long
term protection. This has stimulated the
obtention of serogroup A and C capsular
polysaccharide meningococcal vaccines conju-
gated with proteins.23 These vaccines have been
tested in Africa and the UK, with promising
results.24–29
The excellent results obtained in Catalonia
in controlling the SCMD upsurge by mass vac-
cination supports both the recently taken deci-
sion of the UK Medicines Control Agency to
license production of the new conjugated
meningococcal C polysaccharide vaccine with-
out implementing field trials of eYcacy and the
English Government’s decision to begin mass
vaccination of children and young people.30
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Appendix
As suggested by Kleinbaum et al7 and Ewell31
Y1 e Y0 denote the number of person years of fol-
low up in vaccinated and non-vaccinated respec-
tively in whom C, and c1 y c0 cases of infection have
been observed in the corresponding groups. It is
supposed that the incidence in the respective groups
are independent. In this case, the relative risk (RR) is
calculated by:
Firstly, the natural log transformation of the rela-
tive risk is calculated, as we assume the asymptotic
normality of this transformation.
The variance of this new variable (ln_RR) is
obtained
and approximating var(ln(c1/Yi)),i = 0, 1, by Taylor’s
series we obtain
Substituting (a3) for (a2), we obtain
According to the hypothesis of asymptotic nor-
mality of the transformation mentioned above, the
confidence intervals calculated at (1-á)% for the
variable ln_RR are obtained by the following
equation
and thus, the lower and upper limits of the relative
risk, named RRl y RRu respectively are obtained by
the equation
Finally, the confidence intervals of vaccine
eVectiveness are calculated in function of the
intervals obtained for the relative risk using the
expression (a6):
(VEl, VEu) = (1-RRu, 1-RRl)
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